Though some biological pathology may be driven by BTK and B cells in SLE and SJ, as is evidenced by BTK inhibition altering pathology associated with B cells, its involvement in clinically meaningful pathology appears to be limited, reducing any potential therapeutic benefit of BTK inhibitors. The gene discussed is BTK; the disease is systemic lupus erythematosus.